A3P Barrier Technologies - Lyophilization

Isolators, RABS, Lyophilization, Biological & Enzymatic Indicators, Indirect product contact surfaces, Gloves, Campaign, URS & Design

A3P Barrier Technologies - Lyophilization

When?

June 25 & 26, 2025

Where?

Tours, France

Format?

Conferences, Partner Sessions & Exhibition

Introduction

Pharmaceutical regulatory standards and industry best practices are constantly evolving as demand for sterile drug production capacity grows. Annex 1 is the international reference text for the latest standards in sterile drug manufacturing. It encourages the use of innovative technologies, including barrier technologies, which are becoming essential. Appendix 1 also details the requirements for freeze-drying/freeze dryers more precisely and opens the door to new strategies.
While Annex 1 makes multiple references to “barrier technologies” with the main objective of reducing direct interactions between sources of contamination and aseptic processes, the requirements for interfaces with freeze dryers remain somewhat vague, but represent a real challenge at the industrial level. This is why the “Barrier Technologies” and “Freeze-Drying” GICs have decided to join forces for this event.
During these A3P Technologies Barriers and Freeze Drying 2025 days, we will address the future challenges facing our industry through technical and regulatory topics and provide answers through practical applications:
- Regulatory update
- Managing weak points: ergonomics, transfers, integrity/glove management
- Challenges for isolator set-up of indirect product contact surfaces (parts in contact with caps)
- Specific features related to RABS
- Use of new technologies in the design phases (augmented/virtual reality)
- Campaign mode on a freeze dryer with automatic loading under a technological barrier
- Challenges at the isolator/freeze dryer interfaces
- Issues related to biological indicators and prospects with enzymatic indicators

And many other topics presented by two enthusiastic GICs!

Official conference language: French 
Simultaneous translation: English
ATTENDENT
EXHIBITION

PROGRAM

Related articles

Barrier Technologies & Revision of Annex 1: requirements & operational responses for manufacturers

La Vague 76 / January 2023
The final official version of Annex 1 (Manufacture of Sterile Medicinal Products – Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use), dated 22 August 2022, was published on 25 August 2022. This final version was eagerly awaited by manufacturers and follows a long revision process initiated in 2015 by a working group made up of GMP/GDP inspectors and PIC/S representatives (Inspection Working Group – IWG) and a consultation process led by different associations such as A3P, PDA, PHSS, ISPE, EFPIA …
Button

GMP Annex 1 and Lyophilization

La Vague 76 / January 2023
The production of pharmaceutical products is subject to a set of rules and guidelines, notably the EU -Guidelines to Good Manufacturing Practice (GMP).  The purpose of GMP is to control the quality of products manufactured by holders of a Marketing Authorization (MA). .
Button

Introduction to ASTM E3263-20 "Standard Practice For Qualification Of Visual Inspection of Pharmaceutical Manufacturing Equipment And Medical Devices For Residues"

La Vague 69 / April 2021
Visual inspection has been widely used for many years after equipment cleaning by the pharmaceutical, biotechnology, and medical device industries to release equipment and devices. However, visual inspection has never been proven to be an effective, reliable, or safe method to use.
Button